Last $165.33 USD
Change Today +1.83 / 1.12%
Volume 279.7K
JAZZ On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

jazz pharmaceuticals plc (JAZZ) Snapshot

Open
$163.18
Previous Close
$163.50
Day High
$167.33
Day Low
$161.65
52 Week High
12/8/14 - $183.84
52 Week Low
05/9/14 - $120.38
Market Cap
10.0B
Average Volume 10 Days
803.4K
EPS TTM
$1.27
Shares Outstanding
60.5M
EX-Date
--
P/E TM
129.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for JAZZ PHARMACEUTICALS PLC (JAZZ)

jazz pharmaceuticals plc (JAZZ) Related Businessweek News

No Related Businessweek News Found

jazz pharmaceuticals plc (JAZZ) Details

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients. In addition, it offers products in the areas of hematology and oncology drugs, such as Asparec, which is in Phase I clinical trial for the treatment of patients with ALL with E.coli asparaginase hypersensitivity; Defibrotide for the treatment of severe VOD; and Leukotac, an anti-CD25 monoclonal antibody that is in Phase III clinical trials and is intended for the treatment of steroid-refractory acute GvHD. The company is headquartered in Dublin, Ireland.

870 Employees
Last Reported Date: 11/4/14

jazz pharmaceuticals plc (JAZZ) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: $771.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $419.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $547.0K
Executive Vice President and General Counsel
Total Annual Compensation: $536.0K
Consultant
Total Annual Compensation: $472.7K
Compensation as of Fiscal Year 2013.

jazz pharmaceuticals plc (JAZZ) Key Developments

Jazz Pharmaceuticals plc Receives FDA Approval For Intravenous Administration Of Erwinaze

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. Prior to this approval, the only approved route of administration for Erwinaze was through intramuscular injection. With the expanded label, the formulation of Erwinaze currently on the market may now be administered to patients by either intravenous infusion or intramuscular injection. The updated product label provides data and information to help physicians understand the different administration options and determine which route of administration is most appropriate for their patients. The FDA approval was based on a pharmacokinetic study of intravenous asparaginase Erwinia chrysanthemi following hypersensitivity to E coli-derived asparaginase. The intravenous administration trial was conducted at 10 centers in the U.S. and recruited a total of 30 patients, of which 24 patients were evaluable for the primary endpoint, which was the proportion of patients having an asparaginase activity level of greater than 0.1 IU/mL 48 hours after dosing.

Jazz Pharmaceuticals Initiates Rolling NDA Submission for Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease

Jazz Pharmaceuticals plc announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for defibrotide for the treatment of severe hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy. Defibrotide has been granted Fast Track Designation to treat severe VOD by the FDA.

Jazz Pharmaceuticals plc Announces First Patients Enrolled in Phase 3 Trial of Xyrem(R) (Sodium Oxybate) in Children and Adolescents Who Have Narcolepsy with Cataplexy

Jazz Pharmaceuticals plc announced that the first patients have been enrolled in a Phase 3 clinical trial to assess the safety and efficacy of Xyrem(R) (sodium oxybate) in children and adolescents aged seven to 17 who have narcolepsy with cataplexy. The FDA approval was based on clinical data in primarily adult patients. While there has been a great deal of interest from the narcolepsy community to understand the utility of Xyrem in children or adolescents, there are no published randomized, placebo-controlled trials of Xyrem in pediatric patients. Given the limited knowledge about the use of Xyrem in children or adolescents, Jazz Pharmaceuticals worked with the FDA and key thought leaders to determine the viability of a clinical study to assess Xyrem in children and adolescents. Based on this work, the FDA submitted a Pediatric Written Request to Jazz Pharmaceuticals. The Xyrem Pediatric Narcolepsy Study is a 52-week, Phase 3 randomized, double-blind, open-label, multicenter clinical trial that will evaluate the safety, efficacy and pharmacokinetics of Xyrem in patients aged seven to 17. The trial will enroll up to 100 pediatric patients globally at sites in the U.S. and several countries in Europe.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JAZZ:US $165.33 USD +1.83

JAZZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $36.47 USD +0.43
Alkermes PLC $56.16 USD +1.02
BioMarin Pharmaceutical Inc $88.18 USD +0.89
Sagent Pharmaceuticals Inc $25.58 USD +0.31
Salix Pharmaceuticals Ltd $114.92 USD -1.18
View Industry Companies
 

Industry Analysis

JAZZ

Industry Average

Valuation JAZZ Industry Range
Price/Earnings 100.0x
Price/Sales 9.2x
Price/Book 7.5x
Price/Cash Flow 67.9x
TEV/Sales 7.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit www.jazzpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.